CTI BIOPHARMA CORP (CTIC) Stock Analyst Earnings Estimates
NASDAQ:CTIC - Nasdaq - US12648L6011 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 53.948M | 127.1M 135.60% | 257.94M 102.94% | 345.55M 33.97% | 473.77M 37.11% | 553.52M 16.83% | 469.3M -15.22% | 537.64M 14.56% | 600.47M 11.69% | ||
| EBITDA YoY % growth | -43.04M -9.32% | -94.806M -120.27% | -77.846M 17.89% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -43.57M -9.14% | -95.332M -118.80% | -79.797M 16.30% | -23.106M 71.04% | 87.327M 477.95% | 162.45M 86.02% | 214.31M 31.92% | 315.74M 47.33% | 276.01M -12.58% | 334.66M 21.25% | 388.21M 16.00% | |
| Operating Margin | N/A | N/A | -147.91% | -18.18% | 33.86% | 47.01% | 45.24% | 57.04% | 58.81% | 62.25% | 64.65% | |
| EPS YoY % growth | -0.69 | -1.08 -56.52% | -0.85 21.30% | -0.28 66.63% | 0.40 242.63% | 0.67 64.87% | 1.04 55.58% | 1.60 54.30% | N/A | N/A | N/A |
All data in USD
| Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 61.35% | -0.06 53.97% | -0.03 75.10% | -0.01 85.72% | 0.01 118.22% | 0.04 168.18% | 0.06 284.37% |
| Revenue Q2Q % growth | 28.221M 128.90% | 32.424M 77.75% | 36.98M 75.40% | 39.399M 63.37% | 45.284M 60.46% | 51.338M 58.33% | 56.8M 53.60% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.18M 61.97% | -3.926M 67.86% | 181.999K 101.34% | 2.678M 129.01% | 7.644M 206.46% | 13.017M 431.53% | 17.679M 9,613.81% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | -0.10 72.97% | -0.12 | 0.02 | 15.56% |
| Q4 2022 Q2Q % growth | -0.14 63.16% | -0.10 | -0.04 | -41.98% |
| Q3 2022 Q2Q % growth | -0.13 50.00% | -0.16 | 0.03 | 18.65% |
| Q2 2022 Q2Q % growth | -0.21 | -0.21 | 0.00 | -2.21% |
| Q1 2022 Q2Q % growth | -0.37 -60.87% | -0.42 | 0.05 | 12.38% |
| Q4 2021 Q2Q % growth | -0.38 -90.00% | -0.29 | -0.09 | -32.26% |
| Q3 2021 Q2Q % growth | -0.26 -73.33% | -0.25 | -0.01 | -2.65% |
| Q2 2021 Q2Q % growth | -0.21 -50.00% | -0.21 | 0.00 | 1.96% |
| Q1 2021 Q2Q % growth | -0.23 -15.00% | -0.22 | -0.01 | -3.67% |
| Q4 2020 Q2Q % growth | -0.20 -42.86% | -0.16 | -0.04 | -24.49% |
| Q3 2020 Q2Q % growth | -0.15 11.76% | -0.16 | 0.01 | 4.09% |
| Q2 2020 Q2Q % growth | -0.14 26.32% | -0.13 | -0.01 | -11.29% |
| Q1 2020 Q2Q % growth | -0.20 -5.26% | -0.13 | -0.07 | -50.83% |
| Q4 2019 Q2Q % growth | -0.14 | -0.23 | 0.09 | 39.00% |
| Q3 2019 Q2Q % growth | -0.17 | -0.23 | 0.06 | 27.54% |
| Q2 2019 Q2Q % growth | -0.19 | -0.19 | 0.00 | 1.96% |
| Q1 2019 Q2Q % growth | -0.19 | -0.21 | 0.02 | 11.30% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | 24.116M 950.81% | 23.407M | 709K | 3.03% |
| Q4 2022 Q2Q % growth | 21.083M | 23.969M | -2.886M | -12.04% |
| Q3 2022 Q2Q % growth | 18.241M | 17.511M | 730K | 4.17% |
| Q2 2022 Q2Q % growth | 12.329M | 9.279M | 3.05M | 32.87% |
| Q1 2022 Q2Q % growth | 2.295M | 1.571M | 724K | 46.09% |
| Q3 2020 Q2Q % growth | -100.00% | % | ||
| Q2 2020 Q2Q % growth | -100.00% | % | ||
| Q1 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -6.62% | 0% | -3674.68% |
| Revenue | 0% | -11.03% | 0% | -20.6% |